Yang 2020.

Study characteristics
Methods	Trial design: case report Type of publication: preprint Setting: hospitalised patient  Recruitment dates: 9 February‐17 March 2020 Country: China Language: English Number of centres: 1 Trial registration number: NR Date of trial registration: NR
Participants	Age: 62 years Gender: female Ethnicity: NR Number of participants (recruited/allocated/evaluated): 1 Severity of disease: critical Co‐morbidities: NR Inclusion criteria: NR Exclusion criteria: NR Previous treatments (e.g. experimental drug therapies, oxygen therapy, ventilation): non‐invasive positive pressure ventilation, high‐flow oxygen therapy, Solu Medrol, Voriconazole, Sulfamethoxazole, Magnesium Isoglycyrrhizinate (MgIG), and Enoxaparin
Interventions	Intervention(s): CP therapy Details of CP: Type of plasma: NR Volume: 400 mL x 2, 200m L x 5  Number of doses: 5 Type of antibody test(s) and antibody‐titre(s): NR Pathogen inactivated: NR RT‐PCR tested: NR Details of donors:  Gender: NR HLA and HNA antibody‐negative: NR Severity of disease: NR Timing from recovery from disease: NR RT‐PCR tested: NR Treatment details, including time of plasma therapy (e.g. early stage of disease): administered in a critically ill patient (on 14, 16, 24, 27 February, 2 March) 2020 Comparator: not applicable Concomitant therapy: non‐invasive positive pressure ventilation, high‐flow oxygen therapy, Solu Medrol, Voriconazole, Sulfamethoxazole, Magnesium Isoglycyrrhizinate (MgIG), and Enoxaparin. Unclear whether these treatments were stopped before plasma transfusion or continuously given Duration of follow‐up: up to 37 days (admitted 9 February‐17 March) Treatment cross‐overs: not applicable Compliance with assigned treatment: good
Outcomes	Primary study outcome(s): NR Primary review outcomes All‐cause mortality at hospital discharge: reported  Time to death: not applicable Secondary review outcomes Number of participants with grade 3 and grade 4 AEs, including potential relationship between intervention and adverse reaction (e.g. TRALI, transfusion‐transmitted infection, TACO, TAD, acute transfusion reactions): NR Number of participants with SAEs: NR Improvement of clinical symptoms, assessed through need for respiratory support at up to 7 days; 8‐15 days; 16‐30 days: reported (off high flow on March 5) 30‐day and 90‐day mortality: not applicable Admission on the ICU: reported Length of stay on the ICU: NR Time to discharge from hospital: reported QoL: NR Additional study outcomes: full blood examination, CT chest findings, inflammatory markers (IL1, IL2R, IL6, TNFalpha, IL8, IL10)
Notes	Sponsor/funding: COVID‐19 Rapid Response Call from Huazhong University of Science and Technology; National Natural Science Foundation of China COIs: the study authors have no potential conflicts of interest to disclose Other: nil